SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Alexion Pharmaceuticals, Inc. (ALXN) -- Ignore unavailable to you. Want to Upgrade?

To: Robohogs who wrote (764)3/26/2007 9:38:04 PM
From: rkrw  Respond to of 824
 
alxn said they're committed to all patients getting the drug. If i were an insurer I'd balk, or at least make an offer based on a real pharmaco-economic analysis, then let alxn pay for it.



To: Robohogs who wrote (764)3/26/2007 10:25:37 PM
From: keokalani'nui  Read Replies (1) | Respond to of 824
 
< I am assuming once drug company gets involved, insurance is no longer good and drug company gets ZERO revenue>

Insurance co doesn't care who pays co-pay. The co-pay for them is not policy just cash flow.

You support my point about the lifetime cap. Mine is 2 also. If I was just diagnosed with PNH my coverage would run out four years before I was likely to have a thrombotic event.

...why not $1m/yr?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News